{"id":3687,"date":"2026-05-12T14:15:26","date_gmt":"2026-05-12T11:15:26","guid":{"rendered":"https:\/\/www.welovecycling.com\/ee\/?p=3687"},"modified":"2026-05-12T14:15:26","modified_gmt":"2026-05-12T11:15:26","slug":"uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise","status":"publish","type":"post","link":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/","title":{"rendered":"Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise"},"content":{"rendered":"<h3><strong>Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.<\/strong><\/h3>\n<p><!--more--><\/p>\n<h2><strong>Reaalelulised tulemused vs kliinilised uuringud<\/strong><\/h2>\n<p>Varasemad randomiseeritud kliinilised uuringud maalisid s\u00fcnge pildi: patsiendid, kes l\u00f5petasid semaglutiidil (Ozempic) v\u00f5i tirsapatiidil (Mounjaro) p\u00f5hinevate GLP-1 ravimite kasutamise, v\u00f5tsid aasta jooksul tagasi \u00fcle poole kaotatud kaalust. See uus reaaleluline uuring, mis avaldati ajakirjas <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816857\/\"><em>Diabetes, Obesity and Metabolism<\/em><\/a>, viitab aga sellele, et igap\u00e4evane kliiniline praktika r\u00e4\u00e4gib teist lugu. Siin on patsientidel paindlikkus oma raviplaane kohandada, sageli tervishoiuteenuse osutajate toel.<\/p>\n<p>&#8220;Meie reaalelulised andmed n\u00e4itavad, et paljud patsiendid, kes l\u00f5petavad semaglutiidi v\u00f5i tirsapatiidi kasutamise, alustavad ravimi v\u00f5tmist uuesti v\u00f5i l\u00e4hevad \u00fcle m\u00f5nele teisele rasvumise ravile, mis v\u00f5ib selgitada, miks nad v\u00f5tavad v\u00e4hem kaalus juurde kui patsiendid randomiseeritud uuringutes,&#8221; selgitab uuringu juhtivteadur Hamlet Gasoyan.<\/p>\n<h2><strong>Numbrid: kaalulangus, kaalut\u00f5us ja stabiilsus<\/strong><\/h2>\n<p>Uuring j\u00e4lgis 7938 \u00fclekaalulist v\u00f5i rasvunud t\u00e4iskasvanut Ohios ja Floridas, kes k\u00f5ik olid alustanud ja seej\u00e4rel l\u00f5petanud GLP-1 ravi 3 kuni 12 kuu jooksul. Tulemused olid silmatorkavad. Rasvumise vastu ravitud patsiendid:<\/p>\n<ul>\n<li>Kaotasid enne l\u00f5petamist keskmiselt 8,4% oma kehakaalust.<\/li>\n<li>V\u00f5tsid aasta p\u00e4rast tagasi vaid 0,5% oma kaalust.<\/li>\n<li>55% v\u00f5ttis p\u00e4rast ravimi katkestamist kaalus juurde, samas kui 45% kas s\u00e4ilitas kaalu v\u00f5i j\u00e4tkas kaalu langetamist.<\/li>\n<\/ul>\n<h3>II t\u00fc\u00fcpi diabeedi ravikuuri patsiendid:<\/h3>\n<ul>\n<li>Kaotasid enne l\u00f5petamist keskmiselt 4,4% oma kehakaalust.<\/li>\n<li>Kaotasid j\u00e4rgneva aasta jooksul veel 1,3%.<\/li>\n<li>44% v\u00f5ttis kaalus juurde, samas kui 56% s\u00e4ilitas kaalu v\u00f5i j\u00e4tkas kaalu langetamist.<\/li>\n<\/ul>\n<p>Need leiud n\u00e4itavad, et kaaluj\u00e4lgimine ei ole universaalne teekond. Paljud patsiendid teevad edusamme isegi p\u00e4rast esialgse ravimi kasutamise l\u00f5petamist, sageli uusi strateegiaid kasutusele v\u00f5ttes.<\/p>\n<h2><strong>Miks patsiendid ravi l\u00f5petavad ja mida nad edasi teevad?<\/strong><\/h2>\n<p>Kulud ja kindlustuskaitse osutusid peamisteks katkestamise p\u00f5hjusteks, millele j\u00e4rgnesid k\u00f5rvaltoimed. Siiski selgus uuringust, et patsiendid otsivad aktiivselt alternatiive:<\/p>\n<ul>\n<li>27% l\u00e4ks \u00fcle teisele ravimile, n\u00e4iteks vanema p\u00f5lvkonna rasvumisravimitele v\u00f5i teisele GLP-1 ravimile.<\/li>\n<li>20% alustas uuesti oma algse ravimi kasutamist.<\/li>\n<li>14% tegeles struktureeritud elustiili sekkumistega, tehes koost\u00f6\u00f6d toitumisspetsialistide v\u00f5i treeninguspetsialistidega.<\/li>\n<li>V\u00e4hem kui 1% valis metaboolse ja bariaatrilise kirurgia.<\/li>\n<\/ul>\n<p>M\u00e4rkimisv\u00e4\u00e4rne on see, et II t\u00fc\u00fcpi diabeedi raviks GLP-1 ravimeid kasutanud patsiendid alustasid ravi t\u00f5en\u00e4olisemalt uuesti, t\u00f5en\u00e4oliselt diabeediravimite j\u00e4rjepidevama kindlustuskaitse t\u00f5ttu.<\/p>\n<h2><strong>J\u00e4tkuva toe roll<\/strong><\/h2>\n<p>Uuring r\u00f5hutab individualiseeritud, pikaajalise hoolduse kriitilist rolli kaaluj\u00e4lgimisel. Nagu dr Gasoyan m\u00e4rgib: &#8220;Paljud patsiendid ei loobu oma rasvumise raviteekonnast, isegi kui nad peavad esialgse ravimi kasutamise l\u00f5petama.&#8221;<\/p>\n<p>Teadlased kavatsevad GLP-1 ravimite kasutamise katkestajate jaoks t\u00e4iendavalt uurida alternatiivsete ravimeetodite t\u00f5husust, eesm\u00e4rgiga pakkuda patsientidele ja arstidele andmetel p\u00f5hinevaid teadmisi teadlike otsuste tegemiseks. Uuringu peamised j\u00e4reldused on j\u00e4rgmised.<\/p>\n<ul>\n<li><strong>Reaalelulised andmed erinevad kliinilistest uuringutest:<\/strong> Patsiendid v\u00f5tavad sageli p\u00e4rast <a href=\"https:\/\/www.welovecycling.com\/wide\/series\/weight-loss-drugs\/\">GLP-1 ravimite<\/a> l\u00f5petamist tagasi palju v\u00e4hem kaalu, kui eeldati, t\u00e4nu alternatiivsetele raviv\u00f5imalustele ja elustiilitoele.<\/li>\n<li><strong>Kindlustus ja kulud on olulised:<\/strong> Finantsbarj\u00e4\u00e4rid on peamine p\u00f5hjus ravi katkestamiseks, eriti nende puhul, kes kasutavad ravimeid pigem rasvumise kui diabeedi raviks.<\/li>\n<li><strong>Pikaajaline tugi toimib:<\/strong> Struktureeritud hooldus ravimite, toitumisspetsialistide v\u00f5i treeninguspetsialistide kaudu m\u00e4ngib kaalulanguse s\u00e4ilitamisel v\u00f5tmerolli.<\/li>\n<\/ul>\n<p>See uuring kinnitab, et kaaluj\u00e4lgimine on d\u00fcnaamiline protsess ning tagasil\u00f6\u00f6ke saab \u00f5igete strateegiate ja toega leevendada. See on hea uudis k\u00f5igile, kes kasutavad v\u00f5i kaaluvad Ozempici v\u00f5i sarnaste GLP-1 ravimite proovimist.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise [&hellip;]<\/p>\n","protected":false},"author":174,"featured_media":3688,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[716,291,289,437],"global-categories":[22],"class_list":["post-3687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tervis-trenn","tag-glp-1-ravimid","tag-ozempic","tag-ulekaalulisus","tag-uus-uuring","global-categories-cycling"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3 (Yoast SEO v25.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise - \u0160koda We Love Cycling - Estonia<\/title>\n<meta name=\"description\" content=\"Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise\" \/>\n<meta property=\"og:description\" content=\"Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/\" \/>\n<meta property=\"og:site_name\" content=\"\u0160koda We Love Cycling - Estonia\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T11:15:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"888\" \/>\n\t<meta property=\"og:image:height\" content=\"592\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"andre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jiri Kaloc\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/\",\"url\":\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/\",\"name\":\"Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise - \u0160koda We Love Cycling - Estonia\",\"isPartOf\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp\",\"datePublished\":\"2026-05-12T11:15:26+00:00\",\"author\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57\"},\"description\":\"Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.\",\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"et\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/#primaryimage\",\"url\":\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp\",\"contentUrl\":\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp\",\"width\":888,\"height\":592},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#website\",\"url\":\"https:\/\/www.welovecycling.com\/ee\/\",\"name\":\"\u0160koda We Love Cycling - Estonia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.welovecycling.com\/ee\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57\",\"name\":\"andre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"et\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g\",\"caption\":\"andre\"},\"url\":\"https:\/\/www.welovecycling.com\/ee\/author\/andre\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise - \u0160koda We Love Cycling - Estonia","description":"Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/","og_locale":"et_EE","og_type":"article","og_title":"Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise","og_description":"Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.","og_url":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/","og_site_name":"\u0160koda We Love Cycling - Estonia","article_published_time":"2026-05-12T11:15:26+00:00","og_image":[{"width":888,"height":592,"url":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp","type":"image\/webp"}],"author":"andre","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jiri Kaloc","Est. reading time":"3"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/","url":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/","name":"Uus uuring n\u00e4itab, mis juhtub, kui inimesed l\u00f5petavad Ozempici kasutamise - \u0160koda We Love Cycling - Estonia","isPartOf":{"@id":"https:\/\/www.welovecycling.com\/ee\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/#primaryimage"},"image":{"@id":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/#primaryimage"},"thumbnailUrl":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp","datePublished":"2026-05-12T11:15:26+00:00","author":{"@id":"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57"},"description":"Clevelandi Kliiniku suur anal\u00fc\u00fcs, mis h\u00f5lmas ligi 8000 patsienti, seab kahtluse alla eelduse, et GLP-1 kaalulangetuse ravimite, nagu Ozempic, kasutamise l\u00f5petamine toob paratamatult kaasa kiire kaalut\u00f5usu. Selle asemel paljastab uuring n\u00fcansirikkama reaalsuse. Vaatame l\u00e4hemalt.","inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/"]}]},{"@type":"ImageObject","inLanguage":"et","@id":"https:\/\/www.welovecycling.com\/ee\/2026\/05\/12\/uus-uuring-naitab-mis-juhtub-kui-inimesed-lopetavad-ozempici-kasutamise\/#primaryimage","url":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp","contentUrl":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2026\/05\/ozemp.webp","width":888,"height":592},{"@type":"WebSite","@id":"https:\/\/www.welovecycling.com\/ee\/#website","url":"https:\/\/www.welovecycling.com\/ee\/","name":"\u0160koda We Love Cycling - Estonia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.welovecycling.com\/ee\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"},{"@type":"Person","@id":"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57","name":"andre","image":{"@type":"ImageObject","inLanguage":"et","@id":"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g","caption":"andre"},"url":"https:\/\/www.welovecycling.com\/ee\/author\/andre\/"}]}},"_links":{"self":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts\/3687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/users\/174"}],"replies":[{"embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/comments?post=3687"}],"version-history":[{"count":2,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts\/3687\/revisions"}],"predecessor-version":[{"id":3690,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts\/3687\/revisions\/3690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/media\/3688"}],"wp:attachment":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/media?parent=3687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/categories?post=3687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/tags?post=3687"},{"taxonomy":"global-categories","embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/global-categories?post=3687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}